{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:40:46Z","timestamp":1791906046772,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ejpb.2016.06.010","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T06:39:54Z","timestamp":1466231994000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine"],"prefix":"10.1016","volume":"105","author":[{"given":"Cord J.","family":"Andreas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Tomaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Muenster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2779-9388","authenticated-orcid":false,"given":"Dorina","family":"van der Mey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Mueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2016.06.010_b0005","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research: Guidance for Industry: Food-effect Bioavailability and Fed Bioequivalence Studies, 2002."},{"key":"10.1016\/j.ejpb.2016.06.010_b0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/mp100149j","article-title":"Physiological parameters for oral delivery and in vitro testing","volume":"7","author":"Mudie","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.06.010_b0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11095-005-8476-1","article-title":"Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability\/bioequivalence studies","volume":"23","author":"Kalantzi","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.06.010_b0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00003088-199937030-00003","article-title":"Effects of food on clinical pharmacokinetics","volume":"37","author":"Singh","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2016.06.010_b0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/bdd.1798","article-title":"Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity","volume":"33","author":"Radwan","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2016.06.010_b0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1146\/annurev.nu.16.070196.002123","article-title":"Effects of food on drug absorption","volume":"16","author":"Welling","year":"1996","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.ejpb.2016.06.010_b0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0163-7258(89)90019-3","article-title":"Effects of food on drug absorption","volume":"43","author":"Welling","year":"1989","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2016.06.010_b0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF01061694","article-title":"Influence of food and diet on gastrointestinal drug absorption: a review","volume":"5","author":"Welling","year":"1977","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejpb.2016.06.010_b0045","first-page":"1106","article-title":"The effect of meal energy content on gastric emptying","volume":"30","author":"Velchik","year":"1989","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejpb.2016.06.010_b0050","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-008-9025-8","article-title":"Current methods for predicting human food effect","volume":"10","author":"Lentz","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2016.06.010_b0055","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1016062224568","article-title":"Estimation of the increase in solubility of drugs as a function of bile salt concentration","volume":"13","author":"Mithani","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.06.010_b0060","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s11095-009-9857-7","article-title":"Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs","volume":"26","author":"Clarysse","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.06.010_b0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11095-008-9749-2","article-title":"Meal-induced acceleration of tablet transit through the human small intestine","volume":"26","author":"Fadda","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.06.010_b0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0378-5173(84)90091-7","article-title":"A comparative study of the gastrointestinal transit of a pellet and a tablet formulation","volume":"21","author":"Davis","year":"1984","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.06.010_b0075","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/jps.24076","article-title":"Use of physiologically based pharmacokinetic models coupled with pharmacodynamic models to assess the clinical relevance of current bioequivalence criteria for generic drug products containing Ibuprofen","volume":"103","author":"Cristofoletti","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.06.010_b0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0378-5173(02)00019-4","article-title":"Solid-state characterization of nifedipine solid dispersions","volume":"236","author":"Vippagunta","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.06.010_b0085","unstructured":"Council of Europe: Europ\u00e4isches Arzneibuch (Ph. Eur.), seventh ed., vol. 3, Strasbourg, France, Grundwerk, nifedipine, 2011, pp 3916."},{"key":"10.1016\/j.ejpb.2016.06.010_b0090","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1002\/jps.23611","article-title":"Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation","volume":"102","author":"Wagner","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.06.010_b0095","doi-asserted-by":"crossref","first-page":"II18","DOI":"10.1161\/01.HYP.5.4_Pt_2.II18","article-title":"Pharmacokinetics and metabolism of nifedipine","volume":"5","author":"Raemsch","year":"1983","journal-title":"Hypertension"},{"key":"10.1016\/j.ejpb.2016.06.010_b0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s002280050092","article-title":"Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine","volume":"50","author":"Bode","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.06.010_b0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.1995.tb04534.x","article-title":"Factors affecting the absolute bioavailability of nifedipine","volume":"40","author":"Rashid","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/j.1552-4604.1983.tb02720.x","article-title":"Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects","volume":"23","author":"Foster","year":"1983","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.ejpb.2016.06.010_b0120","first-page":"S340","article-title":"Clinical pharmacokinetics of calcium channel antagonists","volume":"4","author":"McAllister","year":"1982","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0125","unstructured":"Bayer Vital GmbH: Fachinformation Adalat 5mg\/10mg Weichkapsel (prescriber\u2019s information), Bayer Vital GmbH, 2011."},{"key":"10.1016\/j.ejpb.2016.06.010_b0130","unstructured":"Bayer Pharma AG: Adalat Brand Journey (internet), Bayer Pharma AG."},{"key":"10.1016\/j.ejpb.2016.06.010_b0135","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.1365-2125.2002.01599.x","article-title":"The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast","volume":"53","author":"Schug","year":"2002","journal-title":"Brit. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0928-0987(02)00008-8","article-title":"Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union","volume":"15","author":"Schug","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.06.010_b0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00228-002-0444-7","article-title":"Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast","volume":"58","author":"Schug","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejps.2009.06.010","article-title":"Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses","volume":"38","author":"Garbacz","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.06.010_b0155","unstructured":"A. Ohm, H. Luchtenberg, S. Maegata, W. Opitz, Press Coated DHP Tablets, Google Patents, 1990."},{"key":"10.1016\/j.ejpb.2016.06.010_b0160","unstructured":"Bayer Vital GmbH: Fachinformation Adalat Eins 30\/60mg (prescriber\u2019s information), Bayer Vital GmbH, 2011."},{"key":"10.1016\/j.ejpb.2016.06.010_b0165","unstructured":"The United States Pharmacopeia Convention: United States Pharmacopeia and National Formulary (USP 35-NF 30) \u2013 Nifedipine Monograph, vol. 3, Rockville, MD, 2012, pp. 4050\u20134057."},{"key":"10.1016\/j.ejpb.2016.06.010_b0170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clinthera.2008.01.001","article-title":"Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study","volume":"30","author":"Wonnemann","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2016.06.010_b0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejpb.2015.09.002","article-title":"In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release","volume":"97","author":"Andreas","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.06.010_b0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejpb.2015.03.009","article-title":"In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: choosing the appropriate test media","volume":"93","author":"Markopoulos","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.06.010_b0185","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-010-0223-6","article-title":"Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility","volume":"27","author":"Vertzoni","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.06.010_b0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/ja01607a067","article-title":"Studies on dihydropyridines. II. The photochemical disproportionation of 4-(2\u2032-nitrophenyl)-1,4-dihydropyridines","volume":"77","author":"Berson","year":"1955","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2016.06.010_b0195","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/dmd.31.7.938","article-title":"In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5","volume":"31","author":"Patki","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2016.06.010_b0200","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1016\/S0021-9258(19)89213-X","article-title":"Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism","volume":"261","author":"Guengerich","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2016.06.010_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","article-title":"The human hepatic cytochromes P450 involved in drug metabolism","volume":"22","author":"Wrighton","year":"1992","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0210","doi-asserted-by":"crossref","first-page":"8168","DOI":"10.1016\/S0021-9258(18)68457-1","article-title":"Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines","volume":"263","author":"Guengerich","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2016.06.010_b0215","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1365-2125.1984.tb02569.x","article-title":"The first pass metabolism of nifedipine in man","volume":"18","author":"Waller","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0220","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/(SICI)1099-081X(199708)18:6<509::AID-BDD38>3.0.CO;2-5","article-title":"Extrahepatic first-pass metabolism of nifedipine in the rat","volume":"18","author":"Grundy","year":"1997","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2016.06.010_b0225","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0169-409X(01)00119-3","article-title":"Noncompartmentally-based pharmacokinetic modeling","volume":"48","author":"Veng-Pedersen","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2016.06.010_b0230","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0090-9556(24)15229-4","article-title":"Characterization of human small intestinal cytochromes P-450","volume":"27","author":"Zhang","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2016.06.010_b0235","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1211\/jpp.61.05.0002","article-title":"Cytochrome P450-mediated metabolism in the human gut wall","volume":"61","author":"Thelen","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0240","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02389.x","article-title":"Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract","volume":"60","author":"Thorn","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejpb.2016.06.010_b0250","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2710.2004.00618.x","article-title":"Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms","volume":"30","author":"Odou","year":"2005","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejpb.2016.06.010_b0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jchromb.2006.03.048","article-title":"Development of an HPLC method for the determination of nifedipine in human plasma by solid-phase extraction","volume":"839","author":"Zendelovska","year":"2006","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ejpb.2016.06.010_b0260","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/138620709787581693","article-title":"Simultaneous determination of LogD, LogP, and pK(a) of drugs by using a reverse phase HPLC coupled with a 96-well plate auto injector","volume":"12","author":"Chiang","year":"2009","journal-title":"Comb. Chem. High Throughput Screen"},{"key":"10.1016\/j.ejpb.2016.06.010_b0265","unstructured":"M. Kilic, Die Lipidbox fuer Arzneimittel \u2013 ein systematischer Ansatz fuer die Entwicklung von oralen Lipidformulierungen schwerl\u00f6slicher Arzneistoffe, Thesis, 2013."},{"key":"10.1016\/j.ejpb.2016.06.010_b0270","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejps.2011.04.016","article-title":"Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids","volume":"43","author":"Clarysse","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.06.010_b0275","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejps.2013.08.027","article-title":"A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption","volume":"57","author":"Augustijns","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.06.010_b0280","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2005.08.018","article-title":"Impact of the intragastric location of extended release tablets on food interactions","volume":"108","author":"Weitschies","year":"2005","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2016.06.010_b0285","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejps.2013.09.004","article-title":"Development of a bio-relevant dissolution test device simulating mechanical aspects present in the fed stomach","volume":"57","author":"Koziolek","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.06.010_b0290","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijpharm.2015.11.048","article-title":"Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms","volume":"498","author":"Verwei","year":"2016","journal-title":"Int. J. Pharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116302181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116302181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T18:09:44Z","timestamp":1748974184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641116302181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":58,"alternative-id":["S0939641116302181"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2016.06.010","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2016.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}